Pericytes, new therapeutic target for Alzheimer's disease?

Pericytes, new therapeutic target for Alzheimer's disease?

Alzheimer's disease (AD) is considered to be caused by the accumulation of Abeta oligomers. However, more evidences indicate an important vascular contribution to AD. Recently, Nortley et al. demonstrated the link of Aβ to vascular dysfunction in AD. They found that Abeta oligomers act on pericytes to constrict capillaries via ROS-mediated signaling. The capillary constriction decreases cerebral blood flow and leads to energy lack and neurodegeneration in AD. Their result suggests pericyte-driven mechanisms as new avenues of therapeutic approaches for AD.

arigo offers quality antibodies for studying the contribution of ROS and pericytes in AD pathogenesis.



Angiogenesis Antibody Panel (ARG30328)

Ideal for triple staining

Includes endothelial cell marker CD34 antibody

Includes basement membrane marker Collagen IV antibody

Includes pericyte marker NG2 antibody

Includes vSMC marker alpha-SMA antibody


ROS detection

NOX4 antibody

4-HNE antibody [12F7]

8-OH-dG antibody [15A3]


Pericyte markers

NG2 antibody

Desmin antibody

PDGFRB antibody [RM303]


Reference: Engle et al., (2019) Science. 364(6446):1156-1162.